Taken together, our findings demonstrate that postnatal treatment with the 5-HT2 receptor antagonist ketanserin prevents the emergence of specific sequelae of MS and implicates 5-HT2 receptors in the establishment of affective dysfunction in animals with a history of early stress. This evidence concerns the gene HTR2A and myeloid sarcoma.